Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastases.
Adenosine pathway
CD73
Cancer
Immune checkpoint
Interpretable machine learning
Radiomic biomarker
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 07 2023
27 07 2023
Historique:
received:
09
03
2023
accepted:
30
04
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
epublish
Résumé
Finding a noninvasive radiomic surrogate of tumor immune features could help identify patients more likely to respond to novel immune checkpoint inhibitors. Particularly, CD73 is an ectonucleotidase that catalyzes the breakdown of extracellular AMP into immunosuppressive adenosine, which can be blocked by therapeutic antibodies. High CD73 expression in colorectal cancer liver metastasis (CRLM) resected with curative intent is associated with early recurrence and shorter patient survival. The aim of this study was hence to evaluate whether machine learning analysis of preoperative liver CT-scan could estimate high vs low CD73 expression in CRLM and whether such radiomic score would have a prognostic significance. We trained an Attentive Interpretable Tabular Learning (TabNet) model to predict, from preoperative CT images, stratified expression levels of CD73 (CD73 TabNet provided areas under the receiver operating characteristic curve of 0.95 (95% CI 0.87 to 1.0) and 0.79 (0.65 to 0.92) on the training and hold-out test sets respectively, and outperformed other machine learning models. The TabNet-derived score, termed rad-CD73, was positively correlated with CD73 histological expression in matched CRLM (Spearman's ρ = 0.6004; P < 0.0001). The median time to recurrence (TTR) and disease-specific survival (DSS) after CRLM resection in rad-CD73 Our findings reveal promising results for non-invasive CT-scan-based prediction of CD73 expression in CRLM and warrant further validation as to whether rad-CD73 could assist oncologists as a biomarker of prognosis and response to immunotherapies targeting the adenosine pathway.
Sections du résumé
BACKGROUND
Finding a noninvasive radiomic surrogate of tumor immune features could help identify patients more likely to respond to novel immune checkpoint inhibitors. Particularly, CD73 is an ectonucleotidase that catalyzes the breakdown of extracellular AMP into immunosuppressive adenosine, which can be blocked by therapeutic antibodies. High CD73 expression in colorectal cancer liver metastasis (CRLM) resected with curative intent is associated with early recurrence and shorter patient survival. The aim of this study was hence to evaluate whether machine learning analysis of preoperative liver CT-scan could estimate high vs low CD73 expression in CRLM and whether such radiomic score would have a prognostic significance.
METHODS
We trained an Attentive Interpretable Tabular Learning (TabNet) model to predict, from preoperative CT images, stratified expression levels of CD73 (CD73
RESULTS
TabNet provided areas under the receiver operating characteristic curve of 0.95 (95% CI 0.87 to 1.0) and 0.79 (0.65 to 0.92) on the training and hold-out test sets respectively, and outperformed other machine learning models. The TabNet-derived score, termed rad-CD73, was positively correlated with CD73 histological expression in matched CRLM (Spearman's ρ = 0.6004; P < 0.0001). The median time to recurrence (TTR) and disease-specific survival (DSS) after CRLM resection in rad-CD73
CONCLUSIONS
Our findings reveal promising results for non-invasive CT-scan-based prediction of CD73 expression in CRLM and warrant further validation as to whether rad-CD73 could assist oncologists as a biomarker of prognosis and response to immunotherapies targeting the adenosine pathway.
Identifiants
pubmed: 37501197
doi: 10.1186/s12967-023-04175-7
pii: 10.1186/s12967-023-04175-7
pmc: PMC10375693
doi:
Substances chimiques
Adenosine
K72T3FS567
5'-Nucleotidase
EC 3.1.3.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
507Informations de copyright
© 2023. The Author(s).
Références
United European Gastroenterol J. 2016 Apr;4(2):257-63
pubmed: 27087955
JHEP Rep. 2022 Feb 02;4(4):100443
pubmed: 35243281
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Acta Radiol. 2019 Sep;60(9):1084-1093
pubmed: 30612433
Eur Radiol. 2019 Aug;29(8):4008-4015
pubmed: 30456584
Tumour Biol. 2015 Jul;36(7):5459-66
pubmed: 25677906
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Cancer. 2017 Jun 1;123(11):1904-1911
pubmed: 28241095
Ann Oncol. 2018 Apr 1;29(4):1056-1062
pubmed: 29145561
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Nanotheranostics. 2023 Mar 5;7(3):236-257
pubmed: 37064613
NPJ Genom Med. 2021 Jul 14;6(1):59
pubmed: 34262039
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2556-2567
pubmed: 32917666
J Surg Oncol. 2012 Aug 1;106(2):130-7
pubmed: 22287455
Cancer Res. 2010 Aug 15;70(16):6407-11
pubmed: 20682793
J Clin Oncol. 2007 Oct 10;25(29):4575-80
pubmed: 17925551
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036490
Ann Surg Oncol. 2019 Dec;26(13):4587-4598
pubmed: 31605342
Curr Opin Pharmacol. 2020 Aug;53:66-76
pubmed: 32777746
Sci Rep. 2018 Jan 31;8(1):1922
pubmed: 29386574
Sci Adv. 2020 Jul 10;6(28):eaba6156
pubmed: 32832602
Abdom Radiol (NY). 2019 Jun;44(6):1960-1984
pubmed: 31049614
Front Oncol. 2021 Jun 09;11:659964
pubmed: 34178645
PLoS One. 2020 Apr 6;15(4):e0231227
pubmed: 32251447
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Ann Oncol. 2007 Feb;18(2):299-304
pubmed: 17060484
Crit Rev Oncol Hematol. 2020 Oct;154:103068
pubmed: 32805498
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
Clin Transl Radiat Oncol. 2021 Apr 07;28:97-115
pubmed: 33937530
Gastroenterol Rep (Oxf). 2020 Apr 07;8(2):90-97
pubmed: 32280468
Radiat Oncol. 2022 Dec 30;17(1):217
pubmed: 36585716
J Clin Oncol. 2021 Dec 1;39(34):3789-3799
pubmed: 34520230
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Eur Radiol. 2018 Jul;28(7):3050-3058
pubmed: 29404772
Oncoimmunology. 2020 Apr 23;9(1):1746138
pubmed: 32363113
J Pathol Clin Res. 2021 Jan;7(1):27-41
pubmed: 32902189
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
Nat Rev Cancer. 2017 Dec;17(12):709-724
pubmed: 29059149
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Onco Targets Ther. 2020 Nov 13;13:11645-11658
pubmed: 33223838
JAMA Oncol. 2016 Dec 01;2(12):1636-1642
pubmed: 27541161
Cancer Immunol Res. 2023 Jan 3;11(1):56-71
pubmed: 36409930
Med Image Anal. 2017 Dec;42:60-88
pubmed: 28778026
Expert Rev Precis Med Drug Dev. 2019;4(2):59-72
pubmed: 31080889
Cancer Res. 2015 Nov 1;75(21):4494-503
pubmed: 26363007
J Digit Imaging. 2020 Aug;33(4):937-945
pubmed: 32193665
Oncologist. 2022 Jun 8;27(6):e471-e483
pubmed: 35348765
Ann Oncol. 2017 Jun 1;28(6):1191-1206
pubmed: 28168275